Sagittarius Life Science (TWO:3205) — Market Cap & Net Worth
Market Cap & Net Worth: Sagittarius Life Science (3205)
Sagittarius Life Science (TWO:3205) has a market capitalization of $101.30 Million (NT$3.22 Billion) as of August 1, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #19070 globally and #1044 in its home market, demonstrating a -4.80% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sagittarius Life Science's stock price NT$47.60 by its total outstanding shares 67545631 (67.55 Million). See 3205 capital expenditure intensity to understand how much of operating cash flow is reinvested back into capital assets.
Sagittarius Life Science Market Cap History: 2015 to 2026
Sagittarius Life Science's market capitalization history from 2015 to 2026. Data shows change from $550.97 Million to $101.30 Million (-11.23% CAGR).
Sagittarius Life Science Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sagittarius Life Science's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.32x
Sagittarius Life Science's market cap is 0.32 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $245.87 Million | $1.38 Billion | $268.19 Million | 0.18x | 0.92x |
| 2017 | $147.95 Million | $462.82 Million | -$114.21 Million | 0.32x | N/A |
| 2018 | $98.32 Million | $411.41 Million | -$91.81 Million | 0.24x | N/A |
| 2019 | $110.23 Million | $438.71 Million | -$119.51 Million | 0.25x | N/A |
| 2020 | $72.78 Million | $558.18 Million | -$74.12 Million | 0.13x | N/A |
| 2021 | $58.52 Million | $587.61 Million | -$86.42 Million | 0.10x | N/A |
| 2022 | $86.61 Million | $529.07 Million | -$74.20 Million | 0.16x | N/A |
| 2023 | $111.08 Million | $440.46 Million | -$55.04 Million | 0.25x | N/A |
| 2024 | $67.99 Million | $467.75 Million | -$48.53 Million | 0.15x | N/A |
| 2025 | $109.17 Million | $346.08 Million | -$49.56 Million | 0.32x | N/A |
Competitor Companies of 3205 by Market Capitalization
Companies near Sagittarius Life Science in the global market cap rankings as of August 1, 2026.
Key companies related to Sagittarius Life Science by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Sagittarius Life Science Historical Marketcap From 2015 to 2026
Between 2015 and today, Sagittarius Life Science's market cap moved from $550.97 Million to $ 101.30 Million, with a yearly change of -11.23%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$101.30 Million | -7.21% |
| 2025 | NT$109.17 Million | +60.56% |
| 2024 | NT$67.99 Million | -38.79% |
| 2023 | NT$111.08 Million | +28.26% |
| 2022 | NT$86.61 Million | +48.00% |
| 2021 | NT$58.52 Million | -19.59% |
| 2020 | NT$72.78 Million | -33.98% |
| 2019 | NT$110.23 Million | +12.12% |
| 2018 | NT$98.32 Million | -33.55% |
| 2017 | NT$147.95 Million | -39.83% |
| 2016 | NT$245.87 Million | -55.38% |
| 2015 | NT$550.97 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of Sagittarius Life Science was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $101.30 Million USD |
| MoneyControl | $101.30 Million USD |
| MarketWatch | $101.30 Million USD |
| marketcap.company | $101.30 Million USD |
| Reuters | $101.30 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sagittarius Life Science
Sagittarius Life Science Corp engages in the research, development, and sale of Chinese and western medicines, and health food products in Taiwan and Asia. It also offers organic food, daily necessities, and pet food; and engages in the research and development of biotechnology. Sagittarius Life Science Corp was founded in 1998 and is based in Taipei, Taiwan.